History of Changes for Study: NCT01287741

A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

A study version is represented by a row in the table.
Select two study versions to compare. One each from columns A and B.
Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
Click "Compare" to do the comparison and show the differences.
Select a version's Submitted Date link to see a rendering of the study for that version.
The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
Hover over the "Recruitment Status" to see how the study's recruitment status changed.
Study edits or deletions are displayed in red.
Study additions are displayed in green.

Study Record Versions

Version	Submitted Date	Changes
1	January 31, 2011	None (earliest Version on record)
2	February 15, 2011	Study Status
3	March 15, 2011	Study Status
4	April 18, 2011	Study Status and Contacts/Locations
5	May 18, 2011	Contacts/Locations, Study Status and Oversight
6	June 15, 2011	Contacts/Locations and Study Status
7	July 19, 2011	Contacts/Locations and Study Status
8	August 10, 2011	Recruitment Status, Contacts/Locations and Study Status
9	September 19, 2011	Contacts/Locations and Study Status
10	October 14, 2011	Contacts/Locations and Study Status
11	November 15, 2011	Contacts/Locations and Study Status
12	December 5, 2011	Study Status and Contacts/Locations
13	January 17, 2012	Contacts/Locations, Study Status and Study Design
14	February 15, 2012	Contacts/Locations, Study Status and Study Design
15	February 16, 2012	Eligibility and Study Status
16	March 16, 2012	Contacts/Locations and Study Status
17	March 22, 2012	Contacts/Locations and Study Status
18	April 18, 2012	Contacts/Locations and Study Status
19	May 3, 2012	Study Status, Contacts/Locations, Eligibility, Study Description and Study Identification
20	May 21, 2012	Contacts/Locations and Study Status
21	June 4, 2012	Contacts/Locations, Study Status, Eligibility, Sponsor/Collaborators and Study Identification
22	July 5, 2012	Contacts/Locations, Study Status and Sponsor/Collaborators
23	July 17, 2012	Contacts/Locations and Study Status
24	August 15, 2012	Contacts/Locations and Study Status
25	September 19, 2012	Contacts/Locations and Study Status
26	October 10, 2012	Contacts/Locations and Study Status
27	November 1, 2012	Contacts/Locations and Study Status
28	November 15, 2012	Contacts/Locations and Study Status
29	December 3, 2012	Contacts/Locations and Study Status
30	January 3, 2013	Contacts/Locations and Study Status
31	January 7, 2013	Contacts/Locations and Study Status
32	January 14, 2013	Contacts/Locations and Study Status
33	January 21, 2013	Contacts/Locations and Study Status
34	January 31, 2013	Contacts/Locations and Study Status
35	February 4, 2013	Contacts/Locations and Study Status
36	February 11, 2013	Contacts/Locations and Study Status
37	February 19, 2013	Contacts/Locations and Study Status
38	February 25, 2013	Contacts/Locations and Study Status
39	March 4, 2013	Contacts/Locations and Study Status
40	March 11, 2013	Contacts/Locations and Study Status
41	March 18, 2013	Contacts/Locations and Study Status
42	March 25, 2013	Contacts/Locations and Study Status
43	April 1, 2013	Contacts/Locations and Study Status
44	April 8, 2013	Contacts/Locations and Study Status
45	April 15, 2013	Contacts/Locations and Study Status
46	April 22, 2013	Contacts/Locations and Study Status
47	April 29, 2013	Contacts/Locations and Study Status
48	May 7, 2013	Contacts/Locations and Study Status
49	May 13, 2013	Contacts/Locations and Study Status
50	July 1, 2013	Contacts/Locations and Study Status
51	July 9, 2013	Contacts/Locations and Study Status
52	July 16, 2013	Contacts/Locations and Study Status
53	July 23, 2013	Contacts/Locations and Study Status
54	July 29, 2013	Contacts/Locations and Study Status
55	August 5, 2013	Contacts/Locations and Study Status
56	August 13, 2013	Contacts/Locations and Study Status
57	August 19, 2013	Contacts/Locations and Study Status
58	August 26, 2013	Contacts/Locations and Study Status
59	September 4, 2013	Study Status and Contacts/Locations
60	September 9, 2013	Contacts/Locations and Study Status
61	September 12, 2013	Contacts/Locations and Study Status
62	September 18, 2013	Contacts/Locations and Study Status
63	September 25, 2013	Contacts/Locations and Study Status
64	October 7, 2013	Study Status and Contacts/Locations
65	October 8, 2013	Contacts/Locations and Study Status
66	October 17, 2013	Contacts/Locations and Study Status
67	October 21, 2013	Contacts/Locations and Study Status
68	October 28, 2013	Contacts/Locations and Study Status
69	November 4, 2013	Contacts/Locations and Study Status
70	November 13, 2013	Contacts/Locations and Study Status
71	November 18, 2013	Contacts/Locations and Study Status
72	November 25, 2013	Contacts/Locations and Study Status
73	December 3, 2013	Contacts/Locations and Study Status
74	December 9, 2013	Contacts/Locations and Study Status
75	December 17, 2013	Contacts/Locations and Study Status
76	January 6, 2014	Contacts/Locations and Study Status
77	January 13, 2014	Contacts/Locations and Study Status
78	January 20, 2014	Contacts/Locations, Arms and Interventions, Sponsor/Collaborators and Study Status
79	January 27, 2014	Contacts/Locations and Study Status
80	February 3, 2014	Contacts/Locations and Study Status
81	February 10, 2014	Contacts/Locations and Study Status
82	February 17, 2014	Contacts/Locations, Sponsor/Collaborators and Study Status
83	February 24, 2014	Contacts/Locations and Study Status
84	March 3, 2014	Contacts/Locations and Study Status
85	March 14, 2014	Contacts/Locations and Study Status
86	March 17, 2014	Contacts/Locations and Study Status
87	March 24, 2014	Contacts/Locations and Study Status
88	March 31, 2014	Contacts/Locations and Study Status
89	April 7, 2014	Study Status and Contacts/Locations
90	April 14, 2014	Contacts/Locations and Study Status
91	April 22, 2014	Contacts/Locations and Study Status
92	April 28, 2014	Contacts/Locations and Study Status
93	May 5, 2014	Study Status and Contacts/Locations
94	May 12, 2014	Contacts/Locations and Study Status
95	May 19, 2014	Contacts/Locations and Study Status
96	May 26, 2014	Contacts/Locations and Study Status
97	June 23, 2014	Contacts/Locations, Study Status and Study Description
98	June 30, 2014	Contacts/Locations and Study Status
99	July 7, 2014	Study Status and Contacts/Locations
100	July 14, 2014	Contacts/Locations and Study Status
101	July 21, 2014	Contacts/Locations and Study Status
102	August 4, 2014	Recruitment Status, Study Status, Contacts/Locations and Study Design
103	August 11, 2014	Study Status
104	August 26, 2014	Arms and Interventions and Study Status
105	September 22, 2014	Study Status
106	October 6, 2014	Study Status
107	October 13, 2014	Study Status
108	October 20, 2014	Study Status
109	November 3, 2014	Contacts/Locations and Study Status
110	November 10, 2014	Contacts/Locations and Study Status
111	November 17, 2014	Study Status
112	November 24, 2014	Contacts/Locations and Study Status
113	December 1, 2014	Study Status
114	December 8, 2014	Contacts/Locations and Study Status
115	December 15, 2014	Contacts/Locations and Study Status
116	December 23, 2014	Contacts/Locations and Study Status
117	January 6, 2015	Study Status
118	January 12, 2015	Contacts/Locations, Study Description and Study Status
119	January 19, 2015	Contacts/Locations, Study Description and Study Status
120	February 5, 2015	Study Status, Contacts/Locations and Study Description
121	February 19, 2015	Study Status
122	February 23, 2015	Study Status
123	March 2, 2015	Study Status
124	March 9, 2015	Contacts/Locations and Study Status
125	March 16, 2015	Study Status
126	April 2, 2015	Contacts/Locations and Study Status
127	May 5, 2015	Study Status
128	May 11, 2015	Contacts/Locations and Study Status
129	May 29, 2015	Study Status
130	June 1, 2015	Study Status
131	July 1, 2015	Study Status
132	July 31, 2015	Contacts/Locations and Study Status
133	August 17, 2015	Study Status
134	October 20, 2016	Arms and Interventions, Outcome Measures, Contacts/Locations, Study Status, Study Identification, Eligibility, Conditions and Study Description
135	August 15, 2017	Study Status, Contacts/Locations, Outcome Measures, Arms and Interventions, Results and Eligibility
136	November 9, 2017	Study Status and Contacts/Locations
137	February 20, 2018	Recruitment Status, Contacts/Locations and Study Status
138	April 24, 2018	Contacts/Locations and Study Status
139	May 9, 2018	Study Status and Contacts/Locations
140	July 30, 2018	Contacts/Locations and Study Status
141	April 8, 2019	Recruitment Status, Outcome Measures, Adverse Events, Study Status, Participant Flow, Baseline Characteristics and Contacts/Locations

Comparison Format:

Merged
Side-by-Side

Study Identification


Unique Protocol ID:	BO21005
Brief Title:	A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Official Title:	A Phase III, Multicenter, Open-label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)
Secondary IDs:	2010-024194-39

Study Status


Record Verification:	March 2015
Overall Status:	Active, not recruiting
Study Start:	July 2011
Primary Completion:	August 2015 [Anticipated]
Study Completion:	May 2016 [Anticipated]

First Submitted:	January 31, 2011
First Submitted that Met QC Criteria:	January 31, 2011
First Posted:	February 1, 2011 [Estimate]

Last Update Submitted that Met QC Criteria:	March 2, 2015
Last Update Posted:	March 3, 2015 [Estimate]

Sponsor/Collaborators


Sponsor:	Hoffmann-La Roche
Responsible Party:	Sponsor
Collaborators:	Fondazione Italiana Linfomi - ETS

Oversight


U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring:

Study Description

Brief Summary:

This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with CHOP chemotherapy versus MabThera/Rituxan (rituximab) with CHOP in previously untreated patients with CD20-positive diffuse large B-cell lymphoma. Patients will be randomized to receive either obinutuzumab 1000 mg intravenously (iv) every 21 days or MabThera/Rituxan 375 mg/m2 iv every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) iv every 21 days. Anticipated time on study treatment is 24 weeks.

Detailed Description:

Conditions


Conditions:	Lymphoma, B-Cell
Keywords:

Study Design


Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 3
Interventional Study Model:	Parallel Assignment
Number of Arms:	2
Masking:	None (Open Label)
Allocation:	Randomized
Enrollment:	1418 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: G-CHOP	Drug: CHOP chemotherapy CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) iv every 21 days, 6 or 8 cycles Drug: RO5072759 1000 mg iv every 21 days, 8 cycles (additional doses Days 8 and 15 of Cycle 1) Other Names: GA101
Active Comparator: R-CHOP	Drug: CHOP chemotherapy CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone) iv every 21 days, 6 or 8 cycles Drug: rituximab [MabThera/Rituxan] 375 mg/m2 iv every 21 days, 8 cycles

Outcome Measures


Primary Outcome Measures:
1.	Progression-free survival, assessed by the investigator according to a modified version of the Revised Response Criteria for Malignant Lymphoma [ Time Frame: up to approximately 78 months ]
Secondary Outcome Measures:
1.	Overall survival [ Time Frame: up to approximately 78 months ]
2.	Overall response rate at the end of treatment, assessed by the investigator and the Independent Review Committee (IRC) [ Time Frame: 24 weeks ]
3.	Complete response rate at the end of treatment, assessed by investigator and IRC [ Time Frame: 24 weeks ]
4.	Progression-free survival assessed by the Independent Review Committee [ Time Frame: up to approximately 78 months ]
5.	Event-free survival, defined as time to progression or relapse, or initiation of non-protocol-specified anti-lymphoma therapy, or death, whichever occurs first [ Time Frame: up to approximately 78 months ]
6.	Disease-free survival, assessed by investigator [ Time Frame: up to approximately 78 months ]
7.	Duration of response, assessed by the investigator [ Time Frame: up to approximately 78 months ]
8.	Time to next lymphoma treatment [ Time Frame: up to approximately 78 months ]
9.	Safety: Incidence of adverse events [ Time Frame: up to approximately 78 months ]
10.	Quality of life (Functional Assessment of Cancer Therapy-Lymphoma subscale, Euro-Quality of Life 5D questionnaire, European Organization for Research and Treatment of Cancer Quality of Life Core 30) [ Time Frame: up to approximately 78 months ]
11.	Medical resource utilization (hospitalizations, drug therapies, medical and surgical procedures and treatments) [ Time Frame: up to approximately 78 months ]

Eligibility


Minimum Age:	18 Years
Maximum Age:
Sex:	All
Gender Based:
Accepts Healthy Volunteers:	No
Criteria:	Inclusion Criteria: Adult patients, >/= 18 years of age Previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) At least 1 bi-dimensionally measurable lesion (>1.5 cm in is largest dimension on the CT scan) Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 Adequate hematological function Low-intermediate, intermediate or high-risk IPI score (low-risk IPI score: IPI 1 irrespective of bulky disease or IPI 0 with bulky disease, defined as one lesion >/= 7.5 cm) Exclusion Criteria: History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines Patients with transformed lymphoma and patients with follicular lymphoma IIIB Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation Prior treatment with cytotoxic drugs or rituximab for another condition (e.g., rheumatoid arthritis) or prior use of an anti-CD20 antibody Prior use of any monoclonal antibody within 3 months of the start of Cycle 1 Ongoing corticosteroid use of > 30 mg/day of prednisone or equivalent Primary CNS lymphoma, blastic variant of mantle-cell lymphoma, or histologic evidence of transformation to a Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, and primary cutaneous DLBCL Positive for HIV Active hepatitis B or C infection

Contacts/Locations


Study Officials:	Clinical Trials Study Director Hoffmann-La Roche
Locations:	United States, Alabama
	Birmingham, Alabama, United States, 35291-3300
	United States, Arizona
	Chandler, Arizona, United States, 85224
	Tucson, Arizona, United States, 85704
	United States, California
	Encinitas, California, United States, 92008
	Encinitas, California, United States, 92024
	Los Angeles, California, United States, 90095-6984
	United States, Colorado
	Aurora, Colorado, United States, 80012
	United States, Florida
	Fort Myers, Florida, United States, 33916
	St Petersburg, Florida, United States, 33719
	United States, Georgia
	Macon, Georgia, United States, 31201
	United States, Illinois
	Galesburg, Illinois, United States, 61401
	Joliet, Illinois, United States, 60435
	Niles, Illinois, United States, 60714
	Urbana, Illinois, United States, 61801
	United States, Maine
	Portland, Maine, United States, 04102
	United States, Minnesota
	Saint Louis Park, Minnesota, United States, 55426
	Woodbury, Minnesota, United States, 55125
	United States, New York
	Albany, New York, United States, 12206
	United States, North Carolina
	Charlotte, North Carolina, United States, 28204
	Winston-Salem, North Carolina, United States, 27103
	United States, Ohio
	Middletown, Ohio, United States, 45042
	Sandusky, Ohio, United States, 44870
	United States, Oregon
	Springfield, Oregon, United States, 97477
	United States, South Carolina
	Charleston, South Carolina, United States, 29524
	Columbia, South Carolina, United States, 29210
	United States, Tennessee
	Chattanooga, Tennessee, United States, 37404
	Nashville, Tennessee, United States, 37203
	United States, Texas
	Amarillo, Texas, United States, 79106
	Fort Worth, Texas, United States, 76104
	Houston, Texas, United States, 77030
	New Braunfels, Texas, United States, 78130
	United States, Virginia
	Blacksburg, Virginia, United States, 24060
	Richmond, Virginia, United States, 23230
	Winchester, Virginia, United States, 22601
	United States, Washington
	Tacoma, Washington, United States, 98405
	Wenatchee, Washington, United States, 98801
	Argentina
	Cordoba, Argentina, X5003DCE
	Rosario, Argentina, 2000
	Rosario, Argentina, S2000DSV
	Australia, Queensland
	Cairns, Queensland, Australia, 4870
	Australia, Victoria
	Frankston, Victoria, Australia, 3199
	Melbourne, Victoria, Australia, 3168
	Australia, Western Australia
	Perth, Western Australia, Australia, 6000
	Austria
	Innsbruck, Austria, 6020
	Salzburg, Austria, 5020
	Wien, Austria, 1090
	Brazil, RS
	Porto Alegre, RS, Brazil, 90110-270
	Porto Alegre, RS, Brazil, 90610-000
	Brazil, SC
	Florianopolis, SC, Brazil, 88034-000
	Brazil, SP
	Sao Paulo, SP, Brazil, 01236-030
	Sao Paulo, SP, Brazil, 08270-070
	Canada, Alberta
	Calgary, Alberta, Canada, T2N 4N2
	Edmonton, Alberta, Canada, T6G 1Z2
	Canada, British Columbia
	Vancouver, British Columbia, Canada, V5Z 4E6
	Canada, Nova Scotia
	Halifax, Nova Scotia, Canada, B3H 2Y9
	Canada, Ontario
	Ottawa, Ontario, Canada, K1H 8L6
	Toronto, Ontario, Canada, M2K 1E1
	Toronto, Ontario, Canada, M5G 2M9
	Toronto, Ontario, Canada, M9N 1N8
	Canada, Quebec
	Montreal, Quebec, Canada, H1T 2M4
	Montreal, Quebec, Canada, H2L 4M1
	Montreal, Quebec, Canada, H3A 1A1
	Montreal, Quebec, Canada, H3T 1E2
	Quebec City, Quebec, Canada, G1J 1Z4
	Rimouski, Quebec, Canada, G5L 5T1
	Canada, Saskatchewan
	Saskatoon, Saskatchewan, Canada, S7N 4H4
	China
	Beijing, China, 100021
	Beijing, China, 100034
	Beijing, China, 100071
	Beijing, China, 100142
	Beijing, China, 100730
	Beijing, China, 100853
	Changchun, China, 130021
	Changsha, China, 410006
	Fujian, China, 350001
	Fuzhou, China, 350014
	Guangzhou, China, 510060
	Guangzhou, China
	Hangzhou, China, 310003
	Harbin, China, 150081
	Nanchang, China, 330006
	Nanjing, China, 210008
	Nanjing, China, 210009
	Nanning, China, 530021
	Shanghai, China, 200025
	Shanghai, China, 200032
	Shanghai, China, 200433
	Shenyang, China, 110001
	Suzhou, China, 215004
	Tianjin, China, 300060
	Wuhan, China, 430022
	Wuhan, China, 430023
	Xi'an, China, 710038
	Colombia
	Bogota, Colombia
	Floridablanca, Colombia
	Czech Republic
	Brno, Czech Republic, 625 00
	Hradec Kralove, Czech Republic, 500 05
	Praha 2, Czech Republic, 128 08
	Denmark
	København Ø, Denmark, 2100
	Roskilde, Denmark, 4000
	Århus, Denmark, 8000
	Germany
	Aachen, Germany, 52074
	Berlin, Germany, 10707
	Dresden, Germany, 01307
	Erlangen, Germany, 91054
	Giessen, Germany, 35392
	Heidelberg, Germany, 69120
	Wuerzburg, Germany, 97080
	Hong Kong
	Hong Kong, Hong Kong
	Hungary
	Budapest, Hungary, 1083
	Budapest, Hungary, 1097
	Budapest, Hungary, 1122
	Debrecen, Hungary, 4032
	Gyor, Hungary, 9024
	Kaposvar, Hungary, 7400
	Pecs, Hungary, 7624
	Szeged, Hungary, 6720
	Italy, Calabria
	Reggio Calabria, Calabria, Italy, 89100
	Italy, Campania
	Napoli, Campania, Italy, 80131
	Pagani (Sa), Campania, Italy, 84016
	Italy, Emilia-Romagna
	Bologna, Emilia-Romagna, Italy, 40138
	Reggio Emilia, Emilia-Romagna, Italy, 42100
	Italy, Friuli-Venezia Giulia
	Udine, Friuli-Venezia Giulia, Italy, 33100
	Italy, Lazio
	Roma, Lazio, Italy, 00161
	Italy, Liguria
	Genova, Liguria, Italy, 16132
	Italy, Lombardia
	Brescia, Lombardia, Italy, 25123
	Milano, Lombardia, Italy, 20132
	Milano, Lombardia, Italy, 20133
	Milano, Lombardia, Italy, 20141
	Pavia, Lombardia, Italy, 27100
	Italy, Piemonte
	Alessandria, Piemonte, Italy, 15100
	Ivrea, Piemonte, Italy, 10015
	Novara, Piemonte, Italy, 28100
	Orbassano, Piemonte, Italy, 10043
	Torino, Piemonte, Italy, 10126
	Italy, Puglia
	Bari, Puglia, Italy, 70124
	San Giovanni Rotondo, Puglia, Italy, 71013
	Tricase - Le, Puglia, Italy, 73039
	Italy, Sicilia
	Catania, Sicilia, Italy, 95124
	Messina, Sicilia, Italy, 98165
	Italy, Toscana
	Firenze, Toscana, Italy, 50141
	Pisa, Toscana, Italy, 56100
	Italy, Umbria
	Terni, Umbria, Italy, 05100
	Italy, Veneto
	Treviso, Veneto, Italy, 31100
	Verona, Veneto, Italy, 37130
	Vicenza, Veneto, Italy, 36100
	Japan
	Aichi, Japan, 466-8650
	Chiba, Japan, 260-8670
	Fukuoka, Japan, 812-8582
	Fukuoka, Japan, 830-0011
	Gifu, Japan, 501-1194
	Hokkaido, Japan, 060-8648
	Hyogo, Japan, 650-0047
	Iwate, Japan, 020-8505
	Kanagawa, Japan, 236-0004
	Kyoto, Japan, 606-8507
	Niigata, Japan, 951-8566
	Okayama, Japan, 710-8602
	Osaka, Japan, 545-8586
	Osaka, Japan, 565-0871
	Osaka, Japan, 589-8511
	Shimane, Japan, 693-8501
	Tochigi, Japan, 329-0498
	Tokyo, Japan, 104-0045
	Tokyo, Japan, 105-8470
	Tokyo, Japan, 113-8603
	Tokyo, Japan, 135-8550
	Korea, Republic of
	Gyeonggi-do, Korea, Republic of, 410-769
	Jeollanam-do, Korea, Republic of, 519-763
	Seoul, Korea, Republic of, 110-774
	Seoul, Korea, Republic of, 120-752
	Seoul, Korea, Republic of, 135-710
	Seoul, Korea, Republic of, 137-701
	Seoul, Korea, Republic of, 138-736
	Mexico
	Chihuahua, Mexico, 31000
	Monterrey, Mexico, 64460
	Oaxaca, Mexico, 68000
	Queretaro, Mexico, 7600
	Panama
	Panama City, Panama, 32400
	Peru
	Lima, Peru, 18
	Lima, Peru, 34
	Lima, Peru, Lima 41
	Poland
	Brzozów, Poland, 36-200
	Gdansk, Poland, 80-952
	Lodz, Poland, 93-510
	Lublin, Poland, 20-081
	Warszawa, Poland, 02-781
	Wroclaw, Poland, 50-367
	Russian Federation
	Kazan, Russian Federation, 420029
	Moscow, Russian Federation, 115478
	Nizhny Novgorod, Russian Federation, 603126
	Penza, Russian Federation, 440071
	Petrozavodsk, Russian Federation, 185019
	St Petersburg, Russian Federation, 191024
	Serbia
	Belgrade, Serbia, 11000
	Novi Sad, Serbia, 21000
	Slovakia
	Bratislava, Slovakia, 833 10
	South Africa
	Cape Town, South Africa, 7800
	Groenkloof, South Africa, 0181
	Johannesburg, South Africa, 2193
	Johannesburg, South Africa, 2196
	Pretoria, South Africa, 0044
	Spain
	Barcelona, Spain, 08003
	Barcelona, Spain, 08035
	Barcelona, Spain, 08036
	Barcelona, Spain, 08907
	Madrid, Spain, 28034
	Pontevedra, Spain, 36002
	Sevilla, Spain, 41009
	Toledo, Spain, 45004
	Spain, Navarra
	Pamplona, Navarra, Spain, 31008
	Spain, Tarragona
	Reus, Tarragona, Spain, 43204
	Switzerland
	Aarau, Switzerland, 5001
	Bellinzona, Switzerland, 6500
	Chur, Switzerland, 7000
	Zürich, Switzerland, 8091
	Taiwan
	Taipei, Taiwan, 00112
	Taipei, Taiwan, 100
	Taipei, Taiwan, 112
	Taoyuan, Taiwan, 333
	Thailand
	Bangkok, Thailand, 10330
	Bangkok, Thailand, 10400
	Bangkok, Thailand, 10700
	Khon Kaen, Thailand, 40002
	United Kingdom
	Aberdeen, United Kingdom, AB25 2ZN
	Birmingham, United Kingdom, B9 5SS
	Cambridge, United Kingdom, CB2 0QQ
	Leicester, United Kingdom, LE1 5WW
	Wolverhampton, United Kingdom, WV10 0QP

IPDSharing


Plan to Share IPD:

References


Links:
Available IPD/Information: